Evidence Repository - Clinical Genome Resources

The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Link to SEPIO compliant JSON-LD document

Variant: NM_005343.3(HRAS):c.510G>A (p.Lys170=)

CA135992

45305 (ClinVar)

Gene: HRAS

Condition: RASopathy

Inheritance Mode: Autosomal dominant inheritance

Link to MONDO

UUID: 9a40f720-b52f-4f73-b00a-f4480714a568

Approved on: 2024-09-17

Published on: 2024-10-02

HGVS expressions

NM_005343.3:c.510G>A

NM_005343.3(HRAS):c.510G>A (p.Lys170=)

NC_000011.10:g.532696C>T

CM000673.2:g.532696C>T

NC_000011.9:g.532696C>T

CM000673.1:g.532696C>T

NC_000011.8:g.522696C>T

NG_007666.1:g.7855G>A

ENST00000397594.7:c.*20-66G>A

ENST00000417302.7:c.*79G>A

ENST00000397594.6:c.251-66G>A

ENST00000417302.6:c.*79G>A

ENST00000462734.2:c.*122G>A

ENST00000311189.8:c.510G>A

ENST00000311189.7:c.510G>A

ENST00000397594.5:c.*79G>A

ENST00000397596.6:c.510G>A

ENST00000417302.5:c.*79G>A

ENST00000451590.5:c.510G>A

ENST00000462734.1:n.285G>A

ENST00000478324.5:n.243-66G>A

ENST00000479482.1:n.431G>A

ENST00000493230.5:c.*79G>A

NM_001130442.1:c.510G>A

NM_005343.2:c.510G>A

NM_176795.3:c.*79G>A

NM_001130442.2:c.510G>A

NM_001318054.1:c.273G>A

NM_176795.4:c.*79G>A

NM_005343.4:c.510G>A

NM_001318054.2:c.273G>A

NM_001130442.3:c.510G>A

NM_176795.5:c.*79G>A

Likely Benign

BP4 BP7 BP5 BS1

PP3 PM2 BA1

Evidence Links 0

Expert Panel

RASopathy VCEP

Criteria Specification Information

Criteria Specification: ClinGen RASopathy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for HRAS Version 2.1.0

Criteria Specification Approval History

Criteria Specifications for this VCEP

Evidence submitted by expert panel

RASopathy VCEP

The c.510G>A variant in the HRAS gene is a synonymous (silent) variant (p.Lys170=) at a nucleotide that is not predicted by SpliceAI to impact splicing (BP4, BP7). The filtering allele frequency in gnomAD v4.1.0 is 0.02525% (17/44900 alleles) in the East Asian population meeting BS1. This variant has been identified in patients with an alternate molecular basis for disease (BP5; LMM and GeneDx internal data; GTR ID's: 21766, 26957; ClinVar SCV000062144.5; SCV000168832.9). In summary, this variant meets criteria to be classified as likely benign for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: BS1, BP4, BP5, BP7 (Specification Version 2.1, 09/17/2024)

BP4

Computational prediction tool SpliceAI predicts no impact on splicing (BP4).

BP7

The c.510G>A (p.Lys170=) variant is a synonymous (silent) variant at a nucleotide that is not highly conserved and is not predicted to impact splicing (BP7).

BP5

This variant has been identified in a patient with an alternate molecular basis for disease (BP5; LMM and GeneDx internal data; GTR ID's: 21766, 26957; ClinVar SCV000062144.5; SCV000168832.9).

BS1

The filtering allele frequency in gnomAD v4.1.0 is 0.02525% (17/44900 alleles) in the East Asian population meeting BS1.

PP3

Computational prediction tools and conservation analysis suggest that the p.Lys170= variant does not impact the protein (BP4).

PM2

The filtering allele frequency in gnomAD v4.1.0 is 0.02525% (17/44900 alleles) in the East Asian population meeting BS1.

BA1

The filtering allele frequency in gnomAD v4.1.0 is 0.02525% (17/44900 alleles) in the East Asian population meeting BS1.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.